Literature DB >> 308420

Decreased suppressor cell activity in inflammatory bowel disease.

H J Hodgson, J R Wands, K J Isselbacher.   

Abstract

Studies were performed on eleven patients with inflammatory bowel disease to determine if there was an alteration in concanavalin A (Con A) induced suppressor cell activity. Similar investigations were also performed on twenty-one control subjects and five patients with other inflammatory conditions. Supressor cells were generated by pre-incubation of peripheral blood mononuclear cells with a mitogenic concentration of Con A, followed by treatment with mitomycin C and alpha-methyl mannoside. Under these conditions, cells obtained from normal individuals are then capable of suppressing the Con A-stimulated blast transformation responses of fresh allogeneic lymphocytes in new cultures. We found that in twenty out of twenty-one control subjects, and all five patients with other inflammatory disorders, Con A-stimulated suppressor cell activity was demonstrable. Four patients with inflammatory bowel disease, whose disease was mildly active or was in clinical remission, had elicitable suppressor cell activity which fell within the normal range. In contrast, suppressor cell activity was markedly diminished or absent in seven patients with severe and active inflammatory bowel disease. These studies suggest that an alternation in Con A-stimulated suppressor cells exists in patients with active inflammatory bowel disease, which may contribute, in part, to the persistent inflammation in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308420      PMCID: PMC1541329     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus.

Authors:  N I Abdou; A Sagawa; E Pascual; J Hebert; S Sadeghee
Journal:  Clin Immunol Immunopathol       Date:  1976-09

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Concanavalin A-activated suppressor cells in normal human peripheral blood lymphocytes.

Authors:  C Hubert; G Delespesse; A Govaerts
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

4.  Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

5.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

6.  Further animal evidence of a transmissible agent in Crohn's disease.

Authors:  D R Cave; D N Mitchell; S P Kane; B N Brooke
Journal:  Lancet       Date:  1973-11-17       Impact factor: 79.321

7.  Short-term lymphocyte cultures in regional enteritis.

Authors:  S M Brown; R N Taub; D H Present; H D Janowitz
Journal:  Lancet       Date:  1970-05-23       Impact factor: 79.321

8.  Hodgkin's disease. An immunodepleting and immunosuppressive disorder.

Authors:  J J Twomey; A H Laughter; S Farrow; C C Douglass
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

9.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

10.  In vitro studies of ulcerative colitis. II. Cytotoxic action of white blood cells from patients on human fetal colon cells.

Authors:  P PERLMANN; O BROBERGER
Journal:  J Exp Med       Date:  1963-05-01       Impact factor: 14.307

View more
  40 in total

1.  Antigen induced suppression in peripheral blood and lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  H R Dalton; P Hoang; D P Jewell
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

2.  Gut mucosal lymphocytes in inflammatory bowel disease: isolation and preliminary functional characterization.

Authors:  C Fiocchi; J R Battisto; R G Farmer
Journal:  Dig Dis Sci       Date:  1979-09       Impact factor: 3.199

Review 3.  The immunology of inflammatory bowel disease.

Authors:  J R Lowes; D P Jewell
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Impaired regulation of natural killer cells in immunoglobulin synthesis by peripheral blood mononuclear cells from patients with ulcerative colitis.

Authors:  T Kawase; K Kusugami; H Matsunaga; T Matsuura; K Morise
Journal:  Gastroenterol Jpn       Date:  1990-10

5.  Immune status in healthy relatives of patients with familial Crohn's disease.

Authors:  A Van Gossum; E Dupont; L Schandene; M Cremer; J Wybran
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

6.  Phenotype and functional properties of Vicia villosa agglutinin (VVA) binding T cells in patients with Crohn's disease: detection of contrasuppressor activity in patients lacking extra-intestinal manifestations, abscesses and fistulas.

Authors:  A Raedler; H J Lenz; K Sandgren; A de Weerth; S Enversen; S Schreiber; H G Thiele; H Greten
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Further characterization of lymphocytes from human colonic lamina propria: identification of TG cells.

Authors:  S G ReMine; W Bartnik; R C Bahn; R G Shorter
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

8.  Loss of suppressor T-cells in active inflammatory bowel disease.

Authors:  N J Godin; D B Sachar; R Winchester; C Simon; H D Janowitz
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

9.  HLA B8 and granuloma formation in Crohn's disease.

Authors:  G Holdstock; B Macpherson; W L Beeken
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

10.  Controlled therapeutic trial of levamisole and sulphasalazine in acute ulcerative colitis.

Authors:  A Hermanowicz; A Nowak; L Gajos
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.